Certain Warrants of Sensei Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2021.
August 01, 2021
Share
Certain Warrants of Sensei Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2021. These Warrants will be under lockup for 180 days starting from 3-FEB-2021 to 2-AUG-2021.
Details:
The company's directors, executive officers and substantially all of other stockholders, optionholders and warrantholders, have agreed with the underwriters that for a period of 180 days after the date of this prospectus, subject to specified exceptions, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock, or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that file a registration statement related to common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock.
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
SENSEI BIOTHERAPEUTICS, INC. 
